EPIC-HR：入院していないCOVID-19の高リスク成人患者を対象とした経口PF-07321332/リトナビルとプラセボの比較試験

基本情報

NCT ID

NCT04960202

ステータス

完了

試験のフェーズ

第2/第3相

試験タイプ

介入

目標被験者数

2,091

治験依頼者名

Pfizer

概要

The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)